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relevant cost driver (69% of the total costs) followed by
diagnostic procedures (10%). The duration of the stay in
hospital is the decisive factor for the costs of inpatient
care from TPP’s perspective in Germany. The average
hospitalization length was 19.5 days. Assuming a hospi-
talization rate of 10% the direct medical costs per cp pa-
tient and year were 4,488 DM. CONCLUSION: It could
be shown that treatment of chronic polyarthritis is as
cost-intensive as other chronic diseases. Because of the
growing interest in the development of new concepts of
patient care (e.g. disease management), further cost and
outcome data should be assessed to show the relative
value for money (e.g. with cost-effectiveness analysis) in
order to guarantee an appropriate allocation of resources.
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The National Institute of Clinical Excellence (NICE) is
conducting an appraisal of the new COX-II specific in-
hibitors (celecoxib and rofecoxib). NICE asked the Pri-
mary Care Rheumatology (PCR) society to comment on
the ‘real-life’ clinical and cost-effectiveness of the COX-II
specific inhibitors against NSAIDs and the COX-II selec-
tive inhibitors (etodolac and meloxicam) in the treatment
of arthritis. This poster summarises the findings of the
PCR’s NICE submission. OBJECTIVES: To use evi-
dence-based medicine to compare the ‘real-life’ clinical
and cost-effectiveness of the COX-II specifics versus
NSAIDs and the COX-II selectives, in the treatment of
arthritis and prevention of drug-related gastro-intestinal
(GI) adverse events in primary-care. METHODS: Using
PubMed, a literature review of NSAIDs, COX-II inhibi-
tors (celecoxib, etodolac, meloxicam and rofecoxib) and
‘best-practice’ guidelines in the treatment of arthritis was
undertaken. The review concentrated on the problems of
NSAID-related GI adverse events, their associated treat-
ment costs and whether COX-II inhibitors provide alter-
native, clinically and cost-effective methods of treating
arthritis. RESULTS: NSAID-related GI risk rises signifi-
cantly with patient age. In the UK, NSAID-related deaths
average 2,600 patients annually. The mean, NHS cost of
NSAID-related, GI adverse events is an extra £48 per
NSAID patient per year. COX-II specifics have signifi-
cantly better GI tolerability to NSAIDs. But COX-II spe-
cifics cost the NHS an extra £40.15 minimum annually
for the average NSAID patient. COX-II selectives are
cheaper than COX-II specifics and have significantly higher
GI tolerability than NSAIDs. CONCLUSIONS: COX-II
inhibitors represent a more clinically effective solution
for treating arthritis and reducing GI adverse events in
primary care than NSAIDs. There is a lack of ‘real-life ev-
idence’ to determine for which at risk patients COX-II
specifics are cost-effective over the COX-II selectives and
NSAIDs. Best-practice guidelines support the view that
there is a role for COX-II specifics, COX-II selectives and
NSAIDs in treating arthritis in primary care.
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OBJECTIVE: To summarise the state of knowledge in
terms of economic impact of rheumatoid arthritis (RA), to
highlight the level of aggregation of categories of costs in
different economic evaluations and to identify the burden
of productivity costs in RA. METHODS: Several comput-
erised databases (Medline, Embase, Econlit, OHE HEED,
NHS EED) were searched to identify the relevant studies
for the review. Among the hundreds of records found, 18
were selected for the analysis. The majority of them were
cost of illness studies. At the first stage three main catego-
ries of costs were considered (medical direct costs, non-
medical direct costs, productivity costs) and the economic
impact of each category was quantified. Then subcatego-
ries of costs were investigated in order to assess the grade
of homogeneity in the level of aggregation among differ-
ent studies. RESULTS: Direct medical costs were included
in every study. Total average direct medical costs were in
the range of US$6000 per year (per patient). Among
them, hospital costs constituted in general the largest
amount (from 25 to 40%) followed by medications and
arthritis professional visits. There was considerable lack
of homogeneity in the assessment of cost categories.
Many studies showed a skewed distribution of costs
among patients in relation to their level of severity. Non-
medical direct costs were in general not substantial. By
contrast the economic impact of indirect costs has re-
sulted extremely high, ranging from 1 to 3–4 times the di-
rect costs. Productivity costs are likely to be underesti-
mated given the difficulty of assessing the costs associated
with premature mortality. CONCLUSION: The literature
review indicated a strong need for a standardization in the
assessment of relevant costs for RA. Although there were
differences in the level of aggregation, all studies reported
productivity costs to be the largest category. New drugs
with the ability to reduce the long-term consequences of
RA are likely to have a significant economic impact.
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